Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Priority to NZ627451ApriorityCriticalpatent/NZ627451A/en
Priority claimed from NZ610460Aexternal-prioritypatent/NZ610460A/en
Publication of NZ627451ApublicationCriticalpatent/NZ627451A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Disclosed is a use of a peptide immunogen in the preparation of a medicament for treating a patient, wherein the patient is being treated with a specific antibody containing composition, wherein antibody is susceptible to cleavage by one or more proteases associated with the specific disease being treated, and wherein the peptide is a peptide fragment or analogue representative of a proteolytic cleavage site on IgG produced by the one or more proteases associated with the specific disease being treated by antibody therapy.